Labcorp Targets 5-8% Revenue Growth Through 2029 on Specialty Testing, AI Push — Labcorp Holdings Inc.

Event summary

Labcorp reaffirmed 2026 guidance with revenue between $14.7B-$14.8B, representing 5.4%-6.3% growth.
Company projects 5%-8% compound annual revenue growth and 8.5%-11.5% adjusted EPS growth through 2029.
Strategic priorities include specialty testing in oncology, neurology, and women's health, and AI/robotics integration.
Operating margin expansion of 75-150 basis points expected by 2029.
Labcorp supports 85% of FDA-approved new drugs and therapeutic products in 2025.

The big picture

Labcorp's strategic priorities align with broader industry trends toward personalized medicine and consumer-directed care. The company's global scale and scientific capabilities position it to capitalize on high-growth areas like oncology and neurology, while its push into AI and robotics reflects a broader shift toward technology-driven healthcare solutions. With nearly 71,000 employees serving clients in approximately 100 countries, Labcorp's ability to execute its long-term growth plan will be critical in maintaining its leadership position.

What we're watching

Execution Risk: Whether Labcorp can sustain high-single-digit revenue growth amid increasing competition and regulatory pressures.
Technological Integration: The pace at which AI and robotics adoption will drive operational efficiencies and revenue growth.
Market Positioning: How Labcorp's focus on specialty testing and personalized health solutions will differentiate it in the diagnostics market.